Express News | Overview of A-shares Share Buyback: 36 companies disclosed their buyback progress.

Breakings07:29

Express News | Sunshine Novo: plans to repurchase shares worth 50 million to 0.1 billion yuan.

BreakingsDec 25 18:55

Sunshine Nuohe (688621.SH): Currently, stable synthesis of drugs such as Semaglutide and Tirzepatide has been achieved using solid-phase synthesis technology.

On December 23, Glonghui reported that Sunlight Novo Nordisk (688621.SH) stated on the investor interaction platform that its wholly-owned subsidiary Chengdu Novo Nordisk Shengtai Biotechnology Co., Ltd. has established a distinctive innovative research and development platform for peptide and peptide-like drugs, creating a unique model for innovative drug development. The company is currently able to stably synthesize drugs such as Semaglutide and Teriparatide using solid-phase synthesis technology, and in-depth research can be conducted based on market and business layout. Currently, the company is conducting a total of 6 clinical trial services for GLP-1 class innovative drugs, covering indications for weight loss and blood sugar control, which are in the clinical phase.

Gelonghui FinanceDec 23 15:54

Sunshine Novo (688621.SH): As of now, the trend of new customers and Orders is good.

On December 23, Gelo Exchange reported that Sunshine Novo (688621.SH) disclosed its investor relations activity record showing that the integrated R&D service model of "preclinical + clinical" exhibits significant competitive advantages. This model can fully meet the diverse service needs of clients, thereby enhancing the success rate and efficiency of drug development. This advantage helps strengthen the company's ability to secure Orders. In the face of increasing competition within the Industry, the company has adopted a more proactive market expansion strategy by regularly communicating with clients for project planning to ensure precise alignment of R&D services. As of now, new clients and Orders have been developed.

Gelonghui FinanceDec 23 15:45

Sunshine Novo (688621.SH): Currently, 12 Innovative Drugs have been included in the research and development reserve.

On December 19, Gelonghui reported that Sunshine Novo Nordisk (688621.SH) stated on the investor interaction platform that the company's main Business focuses on the field of drug research services. Due to the differing stages of research projects, their execution cycles vary. During the project advancement process, the company follows the principle of phased payment collection and recognizes revenue according to R&D progress or final delivery of outcomes. Therefore, the company's Business itself does not possess characteristics of quarterly cyclicality. Short-term market fluctuations do not truly reflect the intrinsic value of the enterprise. In recent years, the company has gradually increased its investment in the R&D field each year, especially in the area of Innovative Drugs research and development, through

Gelonghui FinanceDec 19 16:50

Intense competition in CRO has reduced gross margin. Sunlight Nuohe is entering the animal health field to seek new growth points.

①Sun Pharmaceuticals' revenue and net income for the first three quarters of this year have increased compared to the past, but the fierce competition in the industry has led to a decline in gross margin. The chairman revealed that the company is increasing research and development investment. ②In order to find new growth opportunities, Sun Pharmaceuticals has established a subsidiary to further expand its CRO business from the human pharmaceutical field to the animal health field, and has signed service orders with several large animal pharmaceutical companies.

cls.cnDec 2 15:59